Award-winning healthcare advertising agency partners with United Therapeutics to launch new implantable delivery system for popular pulmonary hypertension therapy
Austin, Texas (PRWEB) May 09, 2016
HCB Health, one of the nation’s fastest growing independent healthcare advertising agencies, has been named agency of record for United Therapeutics Corporation’s well-known pulmonary arterial hypertension (PAH) therapy drug Remodulin(R). HCB and UT will launch the Remodulin Implantable System, an implantable drug infusion system for intravenous delivery to PAH patients.
Remodulin is one of the most frequently prescribed parenteral therapies for PAH and has established over 13 years of efficacy for afflicted patients. PAH patients can receive the therapy as a continuous subcutaneous or continuous intravenous infusion, but that intravenous delivery can increase infection risks for patients. In January 2015, United Therapeutics submitted a supplemental New Drug Application to the FDA for Remodulin to support the use of the drug with the Medtronic SynchroMed(R) implantable drug infusion system, including a newly developed catheter. Together with UT, HCB will be launching this combination as the Remodulin Implantable System.
Associate Director of Marketing, Remodulin at United Therapeutics, Greg Bottorff, said that the biotechnology company chose HCB for its healthy mix of pharma and device knowledge.
“Because of the higher infection risks association with continuous intravenous infusion of Remodulin, and the prevalence of PAH among high-risk groups who must minimize infection risks, physicians have conservatively reserved the IV infusion method for patients who can’t easily tolerate the continuous subcutaneous infusion, or for situations where the benefits of that delivery outweighed those risks,” said Bottorff. “The Remodulin Implantable System opens up an effective delivery system for more PAH sufferers, and it was important we have an agency that understands both the pharmacology and device complexities associated with this launch.”
PAH is a progressive condition that affects blood vessels, lungs and heart. In some patients with PAH, the body does not produce enough prostacyclin, a natural substance that keeps blood vessels open and working properly, depriving them of necessary oxygen. Remodulin mimics some of the effects of the natural prostacyclin that these patients lack, making it easier for their hearts to pump blood through their lungs. The therapy may help improve exercise-related PAH symptoms, including shortness of breath and fatigue.
“People of all ages suffer from PAH, and obtaining therapy that can give these patients relief is vital for improving quality of life,” said Amy Dowell, associate partner, EVP Strategy, for HCB. “This is why HCB wakes up every morning – to help pioneers like United Therapeutics transform lives. I am confident our team’s deep experience and ability to uncover disruptive ideas will bring United Therapeutics tremendous value on this campaign launch.”
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company has five approved products on the market today and is relentless in its pursuit of “medicines for life.”(R)
About HCB Health
Celebrating its 15th anniversary, HCB Health is an independent, full-service healthcare communications agency serving the entire healthcare sector, including the pharmaceutical, medical device and biotech industries. Headquartered in the digital mecca of Austin, TX, HCB was among the first agencies to incorporate digital into its professional and patient promotional marketing. Unfettered from constraints that plague larger agency networks, more healthcare companies are discovering that “independent thinking can set you free” – a principle that allows the agency to nimbly serve its clients from its Austin and Chicago offices. HCB is winner of the 2016 Manny Heart Award and Agency of the Year finalist.
To learn more about HCB Health, visit HCBHealth.com, follow us on LinkedIn at linkedin.com/company/hcb-health and on Facebook at facebook.com/HCBHealth, and check out our blog at HCBHealth.com/health-blog.
For the original version on PRWeb visit: http://www.prweb.com/releases/2016/05/prweb13393237.htm